Eli Lilly的库存在Q2中下降,原因是糖尿病和肥胖药物增长放缓,尽管销售量和收入都很高。 Eli Lilly's stock fell in Q2 due to slowing diabetes and obesity drug growth, despite strong sales and earnings.

尽管Mounjaro和Zepbound等产品收入丰厚, Eli Lilly 和 Company的股票却在第二季度下跌, Eli Lilly and Company's stock declined in the second quarter amid concerns over slowing growth in its diabetes and obesity drugs, despite strong revenue from products like Mounjaro and Zepbound. 该公司面临竞争和监管审查的加剧,这影响到投资者的信心。 The company faced increased competition and regulatory scrutiny, which impacted investor confidence. 虽然收入和销售仍然强劲,但未来增长的指导却谨慎谨慎,导致市场估值下降。 While earnings and sales remained robust, guidance for future growth was cautious, leading to a drop in market valuation.